Hansoh Pharmaceutical (03692.HK) Shares Rise Over 2% as NDA for Innovative Drug Oligopeptide Injection Accepted by NMPA

Zhitong Finance APP learned that Hansoh Pharma (03692) opened higher by more than 2%. As of press time, it rose 2.08% to HK$30.42, with a turnover of HK$16.4031 million.

In terms of news flow, Hansoh Pharma announced that on June 3, 2026, the New Drug Application (NDA) for its innovative drug, Olepatide Injection, was accepted by the China National Medical Products Administration (NMPA). The drug is indicated for long-term weight management in adults with obesity or overweight. Olepatide is a once-weekly glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) dual receptor agonist independently developed by the Group.